Lixivaptan BALANCE study is a 650-patient Phase III, global, multi-center, randomized, placebo-controlled, double-blind, study of lixivaptan for hyponatremia in patients with heart failure. The primary objective is to evaluate the safety and effectiveness of lixivaptan, when compared to the placebo, in increasing serum sodium from baseline in heart failure patients with hyponatremia. In previous studies, lixivaptan improved blood sodium levels, lowered body weight and increased urine volume. Those studies suggest that lixivaptan may play an important role in treating hyponatremia and the signs and symptoms of water retention associated with heart failure, Syndrome of Inappropriate Anti-Diuretic Hormone(SIADH), and Liver Cirrhosis with
Human Element engage and impact in the scenarios you will be presented with on a physical and moral level that you approach this world." The game was announced on June 1, 2012, and more details were released in the July edition of "Game Informer". On July 19, 2012, Robotoki's president Robert Bowling announced that "Human Element" would have an episodic prequel released exclusively on the Ouya, as a first-party title. But it was later announced that the studio decided to cancel the Ouya version of Human Element "very early on" and switch focus to the open-world experience on other more powerful platforms.